多巴胺D2受体激活 阻断GluA2 / ROS正反循环,以异化慢性偏头痛相关的疼痛敏感化
Wei Zhang1, Xiaoyan Zhang2, Ming Lei1
1Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Antioxidants (Basel, Switzerland)
|June 27, 2024
概括
研究人员发现,阻断GluA2内细胞分裂可以通过减少流入和氧化应激来缓解慢性偏头痛. 多巴胺D2受体激活和ligustrazine也显示了对偏头痛的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性偏头痛是一种令人衰弱的神经系统疾病,具有未满足的治疗需求.
- AMPA受体与疼痛有关,但它们在慢性偏头痛中的调节仍然不清楚.
- 之前的研究已经确定了多巴胺D2受体作为潜在的治疗点.
研究的目的:
- 调查GluA2 AMPA受体内细胞在慢性偏头痛病理生理学中的作用.
- 探索向GluA2内细胞和多巴胺D2受体的治疗潜力.
主要方法:
- 在慢性偏头痛大鼠模型中检查了表面GluA2水平.
- 利用Tat-GluR23Y,一种内细胞酶抑制剂,评估其对疼痛敏感性,流入和线粒体功能的影响.
- 研究了反应性氧物种 (ROS) 在全氧体和GluA2内细胞分裂中的作用.
- 评估了多巴胺D2受体激活和ligustrazine对慢性偏头痛模型的影响.
主要成果:
- 在慢性偏头痛大鼠中观察到降低的表面GluA2水平.
- 抑制GluA2内细胞分裂缓解了类似偏头痛的疼痛,减少了的流入,并减轻了线粒体功能障碍和ROS生成.
- 发现ROS诱导了全和GluA2内细胞分裂,创造了一个积极的反循环.
- 多巴胺D2受体激活和ligustrazine通过中断GluA2 / ROS反循环来抑制疼痛敏感性.
结论:
- 在慢性偏头痛的发病过程中,GluA2内细胞分裂起着至关重要的作用.
- 准GluA2内细胞分解和激活多巴胺D2受体是慢性偏头痛的有希望的治疗策略.
- 利古斯特拉通过多巴胺D2受体调节ROS产生和 nociception,显示出治疗慢性偏头痛的潜力.
相关概念视频
Analgesia and Pain Management
573
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
573
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.3K
Opioid Receptors: Overview
708
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
708
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
299
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
299
GPCR Desensitization
5.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.9K


